Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ATS 2026

American Thoracic Society (ATS) - 122nd International Conference - 2026

May 15 - 20, 2026

  1. All
  2. FASENRA (benralizumab)
  3. BREZTRI/TRIXEO
  4. TEZSPIRE (tezepelumab)
  5. tozorakimab (MEDI3506)
  6. AIRSUPRA (albuterol/budesonide)
  7. NOVELTY
  8. Respiratory Unbranded
  9. Sunakiment (AZD8630/AMG104)

PDF

Benralizumab add-on therapy in patients with eosinophilic asthma uncontrolled on medium dose inhaled corticosteroid-long-acting β2-agonist (ICS-LABA) versus conventional escalation to high-dose ICS-LABA: design of the randomized BRISOTE study

PDF

Changes in mucus density and length following benralizumab treatment of severe eosinophilic asthma observed with functional respiratory imaging

PDF

Health-related quality of life improvements with benralizumab in patients with hypereosinophilic syndrome: results from the phase 3 NATRON study

HTML

AI-Driven Quantitative CT Analysis of Structural Lung Changes After Benralizumab in Severe Asthma

HTML

Efficacy and Safety of Benralizumab in Chinese Patients with Severe Eosinophilic Asthma: 16-week Results from a Phase IIIb Study of Step-down Maintenance Therapy (STEP)

PDF

An indirect comparison of budesonide/glycopyrrolate/formoterol fumarate versus fluticasone/umeclidinium/vilanterol in adults with uncontrolled asthma from a US perspective: a systematic review and network meta-analysis

PDF

The real-world effectiveness of stepping up to high-dose ICS/LABA in patients with asthma - the Japanese experience

PDF

Real-world effectiveness of budesonide/glycopyrrolate/formoterol fumarate on observed COPD exacerbations and healthcare costs by eosinophil level: results from the US ARCTOS study

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on lung function and exacerbations by baseline asthma characteristics in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on lung function and exacerbations by baseline demographics in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on patient reported outcomes and symptoms in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on time to first severe exacerbation and number needed to treat

PDF

A study evaluating the pharmacodynamic equivalence and safety of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a propellant in participants with COPD

PDF

Systemic exposure bioequivalence of budesonide/glycopyrrolate/formoterol fumarate inhaler components (320/36/9.6 µg/dose) with a next generation propellant versus hydrofluoroalkane-134a

HTML

Reduction in COPD exacerbations following prompt triple therapy initiation after hospital discharge: Results from the MITOS EROS discharge study (US)

PDF

Beyond the mucus score: Tezepelumab improves quantitative mucus plugging metrics in moderate-to-severe uncontrolled asthma

PDF

Demographic and clinical characteristics of tezepelumab users in the United States from December 2021 to May 2025: an electronic medical records study (CROSSROADS-2)

PDF

Efficacy and safety of tezepelumab versus placebo in reducing OCS use in OCS-dependent patients with severe asthma: results from the phase 3 SUNRISE study

PDF

Improvements in asthma symptoms and health-related quality of life after tezepelumab initiation in patients with severe asthma: patient exit interview results from the US phase 4 PASSAGE study

PDF

Tezepelumab improves severe asthma symptoms in the first days of treatment compared with placebo in NAVIGATOR

PDF

Effect of tezepelumab on systemic corticosteroid use for exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease by blood eosinophil count: the COURSE study

PDF

Tezepelumab was associated with lower rates of COPD-related healthcare resource utilization in patients with moderate to very severe COPD with elevated blood eosinophil counts: results from the phase 2a COURSE study

PDF

Efficacy of tezepelumab on type 2 inflammatory biomarker levels in the nasal lining fluid of patients with CRSwNP and comorbid asthma

PDF

Tezepelumab in diverse real-world patients with severe asthma across different phenotypes and underrepresented populations: final results from the US Phase 4 PASSAGE study

PDF

Systemic gene expression modulated by tezepelumab is associated with reduced eosinophilic inflammation and predictive of clinical response: results from the phase 3 NAVIGATOR study

PDF

Tezepelumab reduces airway resistance in moderate-to-severe asthma overall and among T2-high patients: functional respiratory imaging results from the CASCADE trial

PDF

Indirect treatment comparison of tezepelumab versus other biologics for the treatment of severe asthma in Asia

PDF

Efficacy of tezepelumab across multiple biomarker-defined subgroups in Chinese patients with severe uncontrolled asthma: a post-hoc analysis of the DIRECTION study

HTML

Clinical Characteristics of Chinese Asthma Patients with Biologics: A Baseline Analysis of The PRESENT II Study

PDF

Tozorakimab, an anti-IL-33 antibody, modulates pathways associated with airway inflammation and tissue dysfunction in COPD patients: mechanistic evidence from FRONTIER-4

PDF

Tozorakimab, an anti-interleukin-33 antibody, inhibits T2 and T1 inflammatory pathways in the airways of patients with uncontrolled, early-onset asthma in FRONTIER-3

PDF

Tozorakimab reduces quantitative mucus plugging metrics in patients with moderate-to-severe COPD

PDF

As-needed albuterol-budesonide decreases risk of severe asthma exacerbation in patients ≥18 Years of age using either GINA step-3 or GINA step 4+5 maintenance therapies: MANDALA Post-Hoc Analysis

PDF

Albuterol-budesonide rescue enhances improvements in control compared with albuterol rescue for patients with mild asthma

PDF

Albuterol-budesonide treatment for acute airway obstruction provides enhanced lung function improvement compared to albuterol in mild asthma irrespective of baseline forced expiratory volume in one-second (FEV1)

PDF

Baseline characteristics and follow-up exacerbation rates in patients with asthma using albuterol-budesonide versus albuterol rescue therapy: A retrospective cohort study in the United States

PDF

Impact of as-needed albuterol-budesonide on symptoms in moderate-to-severe-asthma: A MANDALA post-hoc analysis

PDF

Longitudinal patterns of asthma control and medication usage in patients with asthma uncontrolled on medium/high-dose ICS-LABA: insights from the NOVELTY cohort

PDF

Burden of difficult-to-treat asthma: longitudinal outcomes from the NOVELTY cohort

PDF

Clinical and social drivers of triple therapy initiation amongst patients with COPD exacerbations: results from the US DUALITY disparities study

PDF

Characteristics and outcomes in patients with chronic obstructive pulmonary disease (COPD) experiencing frequent COPD exacerbations while on triple therapy: analyses from a real-world cohort - the ANTLIA study

PDF

Chronic obstructive pulmonary disease (COPD) exacerbations before and after completion of specialist visits: results from the DUALITY specialist study

PDF

Clinical outcomes and characteristics of patients with chronic obstructive pulmonary disease (COPD) frequently exacerbating while on triple therapy: Insights from the SIRIUS II-US Study

PDF

Maintenance therapy use among at-risk chronic obstructive pulmonary disease (COPD) patients who have a history of frequent or severe exacerbations in the United States (US): Findings from the DUALITY Patient Journey Study

PDF

Racial/ethnic disparities in copd-related healthcare resource utilization and expenditures following triple therapy initiation: results from the us duality disparities study

PDF

Treatment patterns for chronic obstructive pulmonary disease (COPD) maintenance therapy among Incident and prevalent patients in the United States (US): Findings from the DUALITY Patient Journey Study

PDF

Patient perspectives on nighttime symptoms associated with chronic obstructive pulmonary disease (PNEUMOS): a qualitative study

PDF

Patient preferences for triple therapy inhalers in chronic obstructive pulmonary disease: findings from the us PNEUMOS discrete choice experiment

PDF

Healthcare resource utilization and economic burden among patients with COPD following cardiopulmonary events: Evidence from the ABACOS OUTCOMES study

PDF

Thrombotic events and mortality in patients with hypereosinophilic syndrome: A real-world matched cohort study

PDF

Healthcare resource utilization following human metapneumovirus (hMPV) or respiratory syncytial virus (RSV) diagnosis in adults with chronic obstructive pulmonary disease (COPD): a retrospective, self-controlled claims-based study

HTML

Real-World Clinical Burden of Severe Asthma with Comorbid COPD: Findings from the INSIGHTS Pragmatic Registry

HTML

Clinical factors associated with disease progression in COPD patients with frequent exacerbations: a preliminary analysis of a national cohort study

HTML

Effectiveness of a COPD Quality Standard Bundle in High-Risk Patients in China: A cluster randomized controlled trial in China

HTML

Impact of Quality Standard Implementation on Delaying Composite Clinical Deterioration in High-Risk COPD: The Roles of CAT Score and GOLD Grade

HTML

Implementation of Quality Standard for Patients with Chronic Obstructive Pulmonary Disease in(within) QIP Enhances Adherence to Inhaled Therapy

HTML

Quality Improvement Program Delays Composite Clinical Deterioration in High-Risk COPD: A Cluster-Randomized Trial in China

HTML

Disease Burden and Blood Eosinophils in Chinese Patients with Severe Eosinophilic Asthma: Baseline Analysis of a Phase IIIb Study of Step-down Maintenance Therapy (STEP)

HTML

Improving COPD Care Through Guideline Implementation and Audit of Post-Exacerbation Transition Bundle in China's County-Level Hospitals: An Interim Analysis of BRIDGE-COPD

HTML

A study to assess the safety, pharmacokinetics, and pharmacodynamics of AZD8630, administered once daily via inhalation, for 2 weeks, in adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists

PDF

Benralizumab add-on therapy in patients with eosinophilic asthma uncontrolled on medium dose inhaled corticosteroid-long-acting β2-agonist (ICS-LABA) versus conventional escalation to high-dose ICS-LABA: design of the randomized BRISOTE study

PDF

Changes in mucus density and length following benralizumab treatment of severe eosinophilic asthma observed with functional respiratory imaging

PDF

Health-related quality of life improvements with benralizumab in patients with hypereosinophilic syndrome: results from the phase 3 NATRON study

HTML

AI-Driven Quantitative CT Analysis of Structural Lung Changes After Benralizumab in Severe Asthma

HTML

Efficacy and Safety of Benralizumab in Chinese Patients with Severe Eosinophilic Asthma: 16-week Results from a Phase IIIb Study of Step-down Maintenance Therapy (STEP)

PDF

An indirect comparison of budesonide/glycopyrrolate/formoterol fumarate versus fluticasone/umeclidinium/vilanterol in adults with uncontrolled asthma from a US perspective: a systematic review and network meta-analysis

PDF

The real-world effectiveness of stepping up to high-dose ICS/LABA in patients with asthma - the Japanese experience

PDF

Real-world effectiveness of budesonide/glycopyrrolate/formoterol fumarate on observed COPD exacerbations and healthcare costs by eosinophil level: results from the US ARCTOS study

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on lung function and exacerbations by baseline asthma characteristics in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on lung function and exacerbations by baseline demographics in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on patient reported outcomes and symptoms in inadequately controlled asthma

PDF

Budesonide/glycopyrrolate/formoterol fumarate effects on time to first severe exacerbation and number needed to treat

PDF

A study evaluating the pharmacodynamic equivalence and safety of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a propellant in participants with COPD

PDF

Systemic exposure bioequivalence of budesonide/glycopyrrolate/formoterol fumarate inhaler components (320/36/9.6 µg/dose) with a next generation propellant versus hydrofluoroalkane-134a

HTML

Reduction in COPD exacerbations following prompt triple therapy initiation after hospital discharge: Results from the MITOS EROS discharge study (US)

PDF

Beyond the mucus score: Tezepelumab improves quantitative mucus plugging metrics in moderate-to-severe uncontrolled asthma

PDF

Demographic and clinical characteristics of tezepelumab users in the United States from December 2021 to May 2025: an electronic medical records study (CROSSROADS-2)

PDF

Efficacy and safety of tezepelumab versus placebo in reducing OCS use in OCS-dependent patients with severe asthma: results from the phase 3 SUNRISE study

PDF

Improvements in asthma symptoms and health-related quality of life after tezepelumab initiation in patients with severe asthma: patient exit interview results from the US phase 4 PASSAGE study

PDF

Tezepelumab improves severe asthma symptoms in the first days of treatment compared with placebo in NAVIGATOR

PDF

Effect of tezepelumab on systemic corticosteroid use for exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease by blood eosinophil count: the COURSE study

PDF

Tezepelumab was associated with lower rates of COPD-related healthcare resource utilization in patients with moderate to very severe COPD with elevated blood eosinophil counts: results from the phase 2a COURSE study

PDF

Efficacy of tezepelumab on type 2 inflammatory biomarker levels in the nasal lining fluid of patients with CRSwNP and comorbid asthma

PDF

Tezepelumab in diverse real-world patients with severe asthma across different phenotypes and underrepresented populations: final results from the US Phase 4 PASSAGE study

PDF

Systemic gene expression modulated by tezepelumab is associated with reduced eosinophilic inflammation and predictive of clinical response: results from the phase 3 NAVIGATOR study

PDF

Tezepelumab reduces airway resistance in moderate-to-severe asthma overall and among T2-high patients: functional respiratory imaging results from the CASCADE trial

PDF

Indirect treatment comparison of tezepelumab versus other biologics for the treatment of severe asthma in Asia

PDF

Efficacy of tezepelumab across multiple biomarker-defined subgroups in Chinese patients with severe uncontrolled asthma: a post-hoc analysis of the DIRECTION study

HTML

Clinical Characteristics of Chinese Asthma Patients with Biologics: A Baseline Analysis of The PRESENT II Study

PDF

Tozorakimab, an anti-IL-33 antibody, modulates pathways associated with airway inflammation and tissue dysfunction in COPD patients: mechanistic evidence from FRONTIER-4

PDF

Tozorakimab, an anti-interleukin-33 antibody, inhibits T2 and T1 inflammatory pathways in the airways of patients with uncontrolled, early-onset asthma in FRONTIER-3

PDF

Tozorakimab reduces quantitative mucus plugging metrics in patients with moderate-to-severe COPD

PDF

As-needed albuterol-budesonide decreases risk of severe asthma exacerbation in patients ≥18 Years of age using either GINA step-3 or GINA step 4+5 maintenance therapies: MANDALA Post-Hoc Analysis

PDF

Albuterol-budesonide rescue enhances improvements in control compared with albuterol rescue for patients with mild asthma

PDF

Albuterol-budesonide treatment for acute airway obstruction provides enhanced lung function improvement compared to albuterol in mild asthma irrespective of baseline forced expiratory volume in one-second (FEV1)

PDF

Baseline characteristics and follow-up exacerbation rates in patients with asthma using albuterol-budesonide versus albuterol rescue therapy: A retrospective cohort study in the United States

PDF

Impact of as-needed albuterol-budesonide on symptoms in moderate-to-severe-asthma: A MANDALA post-hoc analysis

PDF

Longitudinal patterns of asthma control and medication usage in patients with asthma uncontrolled on medium/high-dose ICS-LABA: insights from the NOVELTY cohort

PDF

Burden of difficult-to-treat asthma: longitudinal outcomes from the NOVELTY cohort

PDF

Clinical and social drivers of triple therapy initiation amongst patients with COPD exacerbations: results from the US DUALITY disparities study

PDF

Characteristics and outcomes in patients with chronic obstructive pulmonary disease (COPD) experiencing frequent COPD exacerbations while on triple therapy: analyses from a real-world cohort - the ANTLIA study

PDF

Chronic obstructive pulmonary disease (COPD) exacerbations before and after completion of specialist visits: results from the DUALITY specialist study

PDF

Clinical outcomes and characteristics of patients with chronic obstructive pulmonary disease (COPD) frequently exacerbating while on triple therapy: Insights from the SIRIUS II-US Study

PDF

Maintenance therapy use among at-risk chronic obstructive pulmonary disease (COPD) patients who have a history of frequent or severe exacerbations in the United States (US): Findings from the DUALITY Patient Journey Study

PDF

Racial/ethnic disparities in copd-related healthcare resource utilization and expenditures following triple therapy initiation: results from the us duality disparities study

PDF

Treatment patterns for chronic obstructive pulmonary disease (COPD) maintenance therapy among Incident and prevalent patients in the United States (US): Findings from the DUALITY Patient Journey Study

PDF

Patient perspectives on nighttime symptoms associated with chronic obstructive pulmonary disease (PNEUMOS): a qualitative study

PDF

Patient preferences for triple therapy inhalers in chronic obstructive pulmonary disease: findings from the us PNEUMOS discrete choice experiment

PDF

Healthcare resource utilization and economic burden among patients with COPD following cardiopulmonary events: Evidence from the ABACOS OUTCOMES study

PDF

Thrombotic events and mortality in patients with hypereosinophilic syndrome: A real-world matched cohort study

PDF

Healthcare resource utilization following human metapneumovirus (hMPV) or respiratory syncytial virus (RSV) diagnosis in adults with chronic obstructive pulmonary disease (COPD): a retrospective, self-controlled claims-based study

HTML

Real-World Clinical Burden of Severe Asthma with Comorbid COPD: Findings from the INSIGHTS Pragmatic Registry

HTML

Clinical factors associated with disease progression in COPD patients with frequent exacerbations: a preliminary analysis of a national cohort study

HTML

Effectiveness of a COPD Quality Standard Bundle in High-Risk Patients in China: A cluster randomized controlled trial in China

HTML

Impact of Quality Standard Implementation on Delaying Composite Clinical Deterioration in High-Risk COPD: The Roles of CAT Score and GOLD Grade

HTML

Implementation of Quality Standard for Patients with Chronic Obstructive Pulmonary Disease in(within) QIP Enhances Adherence to Inhaled Therapy

HTML

Quality Improvement Program Delays Composite Clinical Deterioration in High-Risk COPD: A Cluster-Randomized Trial in China

HTML

Disease Burden and Blood Eosinophils in Chinese Patients with Severe Eosinophilic Asthma: Baseline Analysis of a Phase IIIb Study of Step-down Maintenance Therapy (STEP)

HTML

Improving COPD Care Through Guideline Implementation and Audit of Post-Exacerbation Transition Bundle in China's County-Level Hospitals: An Interim Analysis of BRIDGE-COPD

HTML

A study to assess the safety, pharmacokinetics, and pharmacodynamics of AZD8630, administered once daily via inhalation, for 2 weeks, in adults with asthma on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States